Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis
NCT ID: NCT01127893
Last Updated: 2021-03-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
1 participants
INTERVENTIONAL
2010-06-15
2010-09-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Long Term Study of the Safety of Tanezumab When Administered By Subcutaneous Injections
NCT00994890
Extension Study Of Tanezumab In Osteoarthritis
NCT00809783
Efficacy And Safety Study Of Tanezumab Subcutaneous Administration In Osteoarthritis - A Subcutaneous/Intravenous Bridging Study
NCT01089725
Long-Term Study Of The Safety Of Tanezumab In Arthritis Patients
NCT00960804
Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee
NCT02528188
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Tanezumab 10 mg
Tanezumab
Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Tanezumab 5 mg
Tanezumab
Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Tanezumab 2.5 mg
Tanezumab
Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tanezumab
Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Tanezumab
Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Tanezumab
Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Triwest Research Associates
La Mesa, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAFETY EXTENSION OF 1027
Identifier Type: OTHER
Identifier Source: secondary_id
A4091032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.